Visão geral da empresa
A digital healthcare company, iRhythm Holdings, Inc., focuses on the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. This business model operates within the Healthcare sector and the Medical Devices industry, positioning the firm as a specialized provider of diagnostic tools rather than a broad pharmaceutical or general equipment manufacturer. The company currently supports a workforce of 2,400 employees, reflecting a significant operational scale within the niche of digital health diagnostics. With a market capitalization of $3.89 billion and trailing twelve-month revenue of $747.14 million, the valuation indicates that the market assigns a substantial premium to the company's intangible assets and growth potential in the cardiac monitoring space. These financial figures suggest that investors are pricing the company based on future expansion into its core ambulatory cardiac monitoring services, specifically the Zio platform, rather than solely on current profitable operations.
Saúde financeira
The company reported revenue of $747.14 million, a net income of -$44.55 million, and an EBITDA of -$30.568 million for the trailing twelve months. The substantial gap between positive revenue of $747.14 million and a net loss of -$44.55 million reveals a cost structure where operating expenses, including research and development and sales costs, are currently exceeding gross profits, a common characteristic for high-growth medical device firms scaling their commercialization efforts. Despite the net loss, the company generated positive free cash flow of $71.67 million, which indicates a strong balance sheet liquidity and provides the financial flexibility to fund operations without immediate reliance on external financing. The company's margins display a clear divergence between top-line efficiency and bottom-line profitability, with a gross margin of 70.6% demonstrating high pricing power or low cost of goods sold, while an operating margin of 4.2% and a profit margin of -6.0% highlight significant operating leverage challenges. On the liability side, the company holds $583.76 million in cash against $731.18 million in debt, resulting in a high debt-to-equity ratio of 478.69, which characterizes a highly leveraged balance sheet typical of capital-intensive expansion phases. Liquidity is robust, evidenced by a current ratio of 4.63, suggesting the company possesses more than four times the current assets required to cover its short-term obligations. Finally, the return on equity stands at -36.6% and the return on assets at -2.4%, metrics that reveal that management is currently deploying capital to generate losses, likely to accelerate market penetration for their ambulatory cardiac monitoring services rather than maximize current shareholder returns.
Avaliação de valorização
Valuation multiples reflect the market's expectations for future earnings normalization, with a trailing P/E ratio of N/A due to current losses and a forward P/E of 144.07. The significant disparity between the unavailable trailing P/E and the elevated forward P/E implies that the market anticipates a rapid earnings trajectory that will eventually justify the current high multiple. The price-to-book ratio is 25.48, indicating that the stock trades at a substantial premium over its book value, driven by the perceived value of its proprietary technology and digital health platform. Alternative valuation metrics further illustrate this premium, with a price-to-sales ratio of 5.21 and an EV/EBITDA of -132.21, suggesting that traditional profitability metrics are insufficient for valuation and that the market is pricing in significant future growth from its cardiac monitoring services. Regarding price levels, the 52-week high is $212.00 and the 52-week low is $93.66. Assuming the current price sits near the recent trading averages implied by the market cap of $3.89B, the stock typically trades within a wide range, often significantly below the 52-week high of $212.00 given the recent volatility and the low of $93.66. The beta is 1.18, which means the stock price is expected to be 18% more volatile than the broader market, reflecting the higher risk profile associated with its leveraged position and the competitive nature of the medical device industry.
Growth & Income
Revenue growth stands at 27.1% year-over-year, while earnings growth is N/A due to current losses; consequently, earnings are not growing faster than revenue because the company is still operating at a loss, implying that revenue expansion is currently being used to scale the business rather than generate immediate profit. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. Since there are no dividends, the payout ratio is not applicable, and the company effectively reinvests all available earnings and cash flow back into the business to fund the development and commercialization of its ambulatory cardiac monitoring services. The overall growth and income profile is defined by aggressive revenue expansion of 27.1% coupled with a complete absence of dividend income, positioning the asset purely as a growth vehicle for investors seeking exposure to digital healthcare solutions.